Back to Lung Cancer
NCT02013206
NCT02013206
Who may be able to join
Who might be able to join this trial:
- You must be 18 years of age or older
- You have been diagnosed with advanced non-small cell lung cancer (a specific type of lung cancer) that has been confirmed by a tissue sample, at a late stage (stage IIIB or IV)
- Your general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (confirm with trial site)
- You have not had any chemotherapy treatment before
Who may not be able to join:
- You have previously received any treatment that targets a protein involved in cell growth called EGFR (Epidermal Growth Factor Receptor)
- There is medical evidence that your cancer has spread to the brain
- You have any ongoing health condition that is currently unstable or poorly controlled
- You are unable to swallow or take medication by mouth
- You have any significant eye problems or eye conditions
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 2
Sponsor
Hoffmann-La Roche
Registry
clinicaltrials_gov
Start date
1 September 2006
Est. completion
1 October 2010
Where this trial is recruiting
🇫🇷 France
🇩🇪 Germany
🇮🇹 Italy
🇳🇱 Netherlands
🇪🇸 Spain
🇬🇧 United Kingdom
Primary endpoints
Non-Progression Rate (NPR) at 8 Weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.